Company / R&D Expense
Taysha Gene Therapies, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$86.4M
FY2025
5-year range
$56.8M / $131.9M
FY2021-FY2025
Trend
+52.2%
vs FY2024
Sector context
#150 of 210
Health Care
What the data says
At $86M, Taysha Gene Therapies, Inc.'s r&d expense ranks #150 of 210 in the Health Care sector. R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $86M.
Based on SEC 10-K filings.
$86M in FY2025 with a 5-year CAGR of +22.1%.
Declined from $91M to $86M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -13.2%
- 5-Year CAGR
- +22.1%
- 10-Year CAGR
- -
Sector benchmark
#150 of 210 in Health CareTop 71% of 210This company $86.4M Sector average $644.1M
▼
-86.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.1%, indicating consistent growth.
- In FY2025, r&d expense increased 52.2% year-over-year.
- Ranks #150 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $86.4M | +52.2% |
| FY2024 | $56.8M | -37.7% |
| FY2023 | $91.2M | -30.9% |
| FY2022 | $131.9M | +0.0% |
| FY2021 | $131.9M | +313.7% |
| FY2020 | $31.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026